<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408410</article-id><article-id pub-id-type="pmc">PMC12101632</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0322017</article-id><article-id pub-id-type="publisher-id">PONE-D-24-10186</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Covid 19</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Pandemics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Europe</subject><subj-group><subject>European Union</subject><subj-group><subject>Belgium</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Virus Testing</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021</article-title><alt-title alt-title-type="running-head">COVID-19 confirmed cases, hospitalizations, vaccination, and international travel in Belgium</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4622-2616</contrib-id><name><surname>Natalia</surname><given-names>Yessika Adelwin</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Molenberghs</surname><given-names>Geert</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Neyens</surname><given-names>Thomas</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1881-0637</contrib-id><name><surname>Hens</surname><given-names>Niel</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Faes</surname><given-names>Christel</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>I-BioStat, Data Science Institute, Hasselt University, Hasselt, Belgium</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>I-Biostat, Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Centre for Health Economics Research and Modelling of Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Amir Aouissi</surname><given-names>Hani</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Environmental Research Center (CRE), Division of Environment, ALGERIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>yessikaadelwin.natalia@uhasselt.be</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0322017</elocation-id><history><date date-type="received"><day>14</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Adelwin Natalia et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Adelwin Natalia et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0322017.pdf">
</self-uri><abstract><p>In the absence of definitive treatments or vaccines, the primary strategy to mitigate the COVID-19 pandemic relied on non-pharmaceutical interventions. By the end of 2020, COVID-19 vaccines had been developed and initiated for preventive purposes. To better understand the association between various mitigation measures and their impact on the pandemic, we analyzed the effect of vaccination coverage, international travel, traveler positivity rates, and the stringency of public health measures on the incidence of COVID-19 cases and hospitalizations at the provincial level in Belgium. We identified several important interactions among the covariates that influence the incidence of COVID-19 confirmed cases. Specifically, the best-fitting model (AIC = 965.658) revealed significant interactions between lagged vaccination coverage and the stringency index, as well as between incoming travel rates and positivity rates. Additionally, when modeling COVID-19 hospitalizations, a significant interaction was observed between the incoming travel rate and the stringency index. Model performance improved substantially when incorporating the incidence of confirmed cases as a covariate (AIC = 1061.516 vs. AIC = 432.708), while highlighting key interactions between confirmed cases and traveler positivity rates, as well as between lagged vaccination coverage and incoming travel rates. These findings underscore the intricate interplay between public health interventions, population immunity, and mobility patterns in shaping the course of the COVID-19 pandemic.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Internal Funds KU Leuven</institution>
</funding-source><award-id>3M190682</award-id><principal-award-recipient>
<name><surname>Neyens</surname><given-names>Thomas</given-names></name>
</principal-award-recipient></award-group><funding-statement>TN gratefully acknowledges funding by the Internal Funds KU Leuven (project number 3M190682). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="1"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its <xref rid="sec014" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its <xref rid="sec014" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Four years have passed since the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic [<xref rid="pone.0322017.ref001" ref-type="bibr">1</xref>]. By the time the pandemic status was officially lifted on May 5, 2023 [<xref rid="pone.0322017.ref002" ref-type="bibr">2</xref>], more than 765 million reported cases and almost seven million related deaths had been reported globally [<xref rid="pone.0322017.ref003" ref-type="bibr">3</xref>].</p><p>In the absence of a treatment or vaccine in 2020, the main mitigation strategy to prevent further escalation of the pandemic involved non-pharmaceutical interventions (NPIs), such as social distancing, use of face masks, and travel restrictions. Early in the pandemic, many countries implemented lockdowns to prevent further transmission or importation of SARS-CoV-2 [<xref rid="pone.0322017.ref004" ref-type="bibr">4</xref>]. Later, many countries adopted travel restrictions based on recent COVID-19 transmission in specific areas. In October 2020, the European Union introduced color-coded zones (green, orange, red, and gray) based on the risk of COVID-19 infections in a specific country to facilitate free movement while maintaining safety [<xref rid="pone.0322017.ref005" ref-type="bibr">5</xref>]. Stricter measures were implemented for travelers originating from high-risk zones. Several studies reported that travel restrictions, particularly on international travel, had a consistent effect on slowing down the spread of COVID-19 [<xref rid="pone.0322017.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0322017.ref008" ref-type="bibr">8</xref>].</p><p>By the end of 2020, vaccines against COVID-19 had reached the market and could be added as a prophylactic measure. Europe started the vaccination campaign in December 2020, and per 23 January 2022, over 827 million vaccine doses had been administered in this region [<xref rid="pone.0322017.ref009" ref-type="bibr">9</xref>]. The first campaign focused on the older age population since COVID-19&#x02019;s severity increases with age and, consequently, hit the older age population hard in many periods [<xref rid="pone.0322017.ref010" ref-type="bibr">10</xref>]. As of May 1, 2022, 79% of the Belgian population had completed full primary COVID-19 vaccination, with 62% of those individuals also receiving a booster dose. Among adults aged 18 years and older, the full primary vaccination coverage was 88%, with 75% of this group having received a booster dose [<xref rid="pone.0322017.ref011" ref-type="bibr">11</xref>].</p><p>Many studies reported the effect of human mobility on the spread of COVID-19 [<xref rid="pone.0322017.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0322017.ref015" ref-type="bibr">15</xref>] as well as the effect of COVID-19 vaccination on the incidence of COVID-19 cases or hospitalizations [<xref rid="pone.0322017.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0322017.ref018" ref-type="bibr">18</xref>]. However, only a few studies reported the effects of human mobility, especially international travel, together with COVID-19 vaccination in the same analysis. Zou <italic toggle="yes">et al.</italic> simulated the influence of vaccination coverage and daily mobility among provinces on COVID-19&#x02019;s effective reproduction number during the Chinese-Spring-Festival travel rush in 2021 [<xref rid="pone.0322017.ref019" ref-type="bibr">19</xref>]. They concluded that vaccination decreases the reproductive number while high daily mobility yield an opposite effect. These results were based mainly on simulated data, thus it is important to evaluate the effect of these variables in a real-world setting.</p><p>Nguyen <italic toggle="yes">et al.</italic> reported the aggravating effect of international travel on the daily COVID-19 incidence in Belgium [<xref rid="pone.0322017.ref020" ref-type="bibr">20</xref>]. However, to our knowledge, no study has assessed the combined effect of COVID-19 vaccination and incoming international travel on confirmed cases and hospitalizations within a single analytical framework. Furthermore, it is crucial to account for additional factors that may influence disease dynamics, such as the positivity rate among incoming travelers and the public health mitigation measures implemented at different time points. To better understand the association between these factors and their impact on the COVID-19 pandemic, we conducted an analysis using publicly available data from Belgium. We focused our analysis on the year 2021, following the implementation of travel restrictions based on color-coded zones and the widespread roll-out of the COVID-19 vaccination campaign. By incorporating data on the positivity rate among incoming travelers and the mitigation measures in place during this time, we aim to provide a more comprehensive assessment of how international travel and vaccination jointly influenced COVID-19 transmission and healthcare burden.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Study area</title><p>Belgium is divided into three regions: Flanders in the north, Wallonia in the south, and the Brussels-Capital Region in the center of Belgium. In 2021, the population of these regions was approximately 6.65 million in Flanders, 3.65 million in Wallonia, and 1.22 million in the Brussels-Capital Region. Both the Flemish and Walloon regions are further subdivided into five provinces, resulting in a total of 11 administrative units included in our analysis, as illustrated in <xref rid="pone.0322017.g001" ref-type="fig">Fig 1</xref>.</p><fig position="float" id="pone.0322017.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0322017.g001</object-id><label>Fig 1</label><caption><title>Border of provinces in Belgium. Regional division is marked with black lines.</title><p>The map is adapted from <ext-link xlink:href="https://statbel.fgov.be/en/open-data/statistical-sectors-2021" ext-link-type="uri">https://statbel.fgov.be/en/open-data/statistical-sectors-2021</ext-link> using R 4.4.1.</p></caption><graphic xlink:href="pone.0322017.g001" position="float"/></fig></sec><sec id="sec004"><title>Data</title><p>Data on daily confirmed COVID-19 cases and hospitalizations at the provincial level, along with weekly cumulative vaccinations at the municipality level, were made publicly available by Sciensano, the Belgian institute for public health [<xref rid="pone.0322017.ref021" ref-type="bibr">21</xref>].</p><p>Until May 23, 2022, all incoming travelers to Belgium, regardless of their mode of transportation, were required to complete a Passenger Locator Form (PLF) either prior to or upon arrival [<xref rid="pone.0322017.ref022" ref-type="bibr">22</xref>]. During this period, travelers arriving from high-risk zones were required to undergo mandatory testing on both day 1 and day 7 post-arrival. Sciensano documented the volume of incoming travelers and their test results in weekly epidemiological reports (available in Dutch, French, and German) [<xref rid="pone.0322017.ref023" ref-type="bibr">23</xref>]. Detailed weekly data on international arrivals and the day 1 post-arrival positivity rate at the provincial level are available up until early April 2022. To maintain consistency in our data and analysis, we restricted our study period to include only data from the year 2021.</p><p>To assess the general influence of travel restriction and other NPIs, we also retrieved the stringency index from Our World in Data [<xref rid="pone.0322017.ref024" ref-type="bibr">24</xref>]. A higher stringency index indicates more stringent policies at the country level during a given period [<xref rid="pone.0322017.ref025" ref-type="bibr">25</xref>]. The general population data in 2021 were obtained from StatBel, the Belgian National Statistics Institute [<xref rid="pone.0322017.ref026" ref-type="bibr">26</xref>].</p></sec><sec id="sec005"><title>Statistical methods</title><p>Let <italic toggle="yes">Y</italic><sub><italic toggle="yes">ijk</italic></sub> be the COVID-19 incidence of confirmed cases per 100,000 individuals (<italic toggle="yes">k</italic>&#x02009;=&#x02009;1) or the COVID-19 hospitalizations per 100,000 individuals (<italic toggle="yes">k</italic>&#x02009;=&#x02009;2) at week <inline-formula id="pone.0322017.e001"><alternatives><graphic xlink:href="pone.0322017.e001.jpg" id="pone.0322017.e001g" position="anchor"/><mml:math id="M1" display="inline" overflow="scroll"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#x02026;</mml:mo><mml:mo>,</mml:mo><mml:mn>52</mml:mn></mml:mrow></mml:math></alternatives></inline-formula> as defined by the International Standard ISO 8601, i.e., each week begins on Monday and week 1 is the first week with at least four days in the new year that contains the first Thursday, in province <inline-formula id="pone.0322017.e002"><alternatives><graphic xlink:href="pone.0322017.e002.jpg" id="pone.0322017.e002g" position="anchor"/><mml:math id="M2" display="inline" overflow="scroll"><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#x02026;</mml:mo><mml:mo>,</mml:mo><mml:mn>11</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. Given the heterogeneity in outcomes across provinces, we used a logarithmic transformation of <italic toggle="yes">Y</italic><sub><italic toggle="yes">ijk</italic></sub> and included province <italic toggle="yes">j</italic> as a random effect. The general proposed model is given by:</p><disp-formula id="pone.0322017.e003"><alternatives><graphic xlink:href="pone.0322017.e003.jpg" id="pone.0322017.e003g" position="anchor"/><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover></mml:mstyle><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>X</mml:mtext></mml:mstyle><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(1)</label></disp-formula><p>with <inline-formula id="pone.0322017.e004"><alternatives><graphic xlink:href="pone.0322017.e004.jpg" id="pone.0322017.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e005"><alternatives><graphic xlink:href="pone.0322017.e005.jpg" id="pone.0322017.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e006"><alternatives><graphic xlink:href="pone.0322017.e006.jpg" id="pone.0322017.e006g" position="anchor"/><mml:math id="M6" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">jk</italic></sub> mutually independent. Here, <inline-formula id="pone.0322017.e007"><alternatives><graphic xlink:href="pone.0322017.e007.jpg" id="pone.0322017.e007g" position="anchor"/><mml:math id="M7" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> represents the outcome-specific fixed intercept and <italic toggle="yes">b</italic><sub>0<italic toggle="yes">jk</italic></sub> denotes the province-specific random intercept. The term <inline-formula id="pone.0322017.e008"><alternatives><graphic xlink:href="pone.0322017.e008.jpg" id="pone.0322017.e008g" position="anchor"/><mml:math id="M8" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> indicates the regression coefficient associated with each predictor, where <italic toggle="yes">n</italic> represents the total number of effects, including any interaction terms, incorporated into the model.</p><p>In general, four main explanatory variables were considered in our analysis:</p><list list-type="order"><list-item><p>The weekly vaccination coverage per province defined as the cumulative population percentage that received full primary vaccination either with 1-dose or 2-doses vaccines. Taking into account that vaccination may have a delayed effect as immunity requires time to develop [<xref rid="pone.0322017.ref027" ref-type="bibr">27</xref>], we also explored the effect of vaccination coverage at lag <italic toggle="yes">l</italic> week as a potential predictor. Given the duration of our study period and the potential for waning immunity [<xref rid="pone.0322017.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0322017.ref029" ref-type="bibr">29</xref>], we used the lagged vaccination coverage up to six months prior to the current week. This variable is denoted as <inline-formula id="pone.0322017.e009"><alternatives><graphic xlink:href="pone.0322017.e009.jpg" id="pone.0322017.e009g" position="anchor"/><mml:math id="M9" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> with <inline-formula id="pone.0322017.e010"><alternatives><graphic xlink:href="pone.0322017.e010.jpg" id="pone.0322017.e010g" position="anchor"/><mml:math id="M10" display="inline" overflow="scroll"><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#x02026;</mml:mo><mml:mo>,</mml:mo><mml:mn>24</mml:mn></mml:mrow></mml:math></alternatives></inline-formula>. On top of this, we also considered the non-linear effect of vaccination and a decrease in the marginal benefit at high vaccination coverage [<xref rid="pone.0322017.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0322017.ref031" ref-type="bibr">31</xref>]; thus we included the inverse of vaccination coverage at lag <italic toggle="yes">l</italic> week, denoted as <inline-formula id="pone.0322017.e011"><alternatives><graphic xlink:href="pone.0322017.e011.jpg" id="pone.0322017.e011g" position="anchor"/><mml:math id="M11" display="inline" overflow="scroll"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula>, in our model selection.</p></list-item><list-item><p>The weekly incoming travel rate (<inline-formula id="pone.0322017.e012"><alternatives><graphic xlink:href="pone.0322017.e012.jpg" id="pone.0322017.e012g" position="anchor"/><mml:math id="M12" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) calculated as the number of incoming travelers (regardless of zone and mandate to get tested) to province <italic toggle="yes">j</italic> at week <italic toggle="yes">i</italic> per 100 inhabitants in that province (also denoted as percentage).</p></list-item><list-item><p>The weekly positivity rate among travelers from high-risk zones (<inline-formula id="pone.0322017.e013"><alternatives><graphic xlink:href="pone.0322017.e013.jpg" id="pone.0322017.e013g" position="anchor"/><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) calculated as the number of positive tests per 100 conducted tests (also denoted as percentage).</p></list-item><list-item><p>The median stringency index at the corresponding week <inline-formula id="pone.0322017.e014"><alternatives><graphic xlink:href="pone.0322017.e014.jpg" id="pone.0322017.e014g" position="anchor"/><mml:math id="M14" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>.</p></list-item></list><p>It is important to note that COVID-19 hospitalizations are a direct consequence of COVID-19 infections. For this reason, we also evaluated an alternative model for hospitalizations that incorporates the incidence of confirmed cases in the same week as an explanatory variable. To avoid confusion, the logarithm of confirmed cases is denoted as <inline-formula id="pone.0322017.e015"><alternatives><graphic xlink:href="pone.0322017.e015.jpg" id="pone.0322017.e015g" position="anchor"/><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> when used as an explanatory variable in the model.</p><p>Considering different dynamics among these variables, we explored several fixed effects variations which include different interaction terms. To reduce the risk of overfitting, we constrained the model to include only two-way interaction terms. The most parsimonious model was selected based on the lowest Akaike information criterion (AIC) value.</p><p>As a sensitivity analysis, we selected a subset of our dataset from week 20 (May 17&#x02013;23), a period in which vaccination coverage had reached at least 10% of the population in each province. Using this subset, we applied the same model selection procedure as that used for the full dataset to evaluate the robustness of our findings. All analyses were performed using R 4.4.1 available from the Comprehensive R Archive Network (CRAN) (<ext-link xlink:href="https://CRAN.R-project.org/" ext-link-type="uri">https://CRAN.R-project.org/</ext-link>).</p></sec></sec><sec sec-type="results" id="sec006"><title>Results</title><sec id="sec007"><title>Exploratory data analysis</title><p>The weekly time trends of variables used in this study are presented in <xref rid="pone.0322017.g002" ref-type="fig">Fig 2</xref>.</p><fig position="float" id="pone.0322017.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0322017.g002</object-id><label>Fig 2</label><caption><title>Time trend of weekly (A) confirmed cases, (B) hospitalizations, (C) vaccination coverage, (D) incoming travel rate, (E) positivity rate among the incoming travelers, and (F) stringency index.</title></caption><graphic xlink:href="pone.0322017.g002" position="float"/></fig><p>Overall, multiple waves of confirmed cases were observed across all provinces (<xref rid="pone.0322017.g002" ref-type="fig">Fig 2A</xref>). A marked increase in the incidence of confirmed cases occurred between weeks 9 (March 1&#x02013;7) and 17 (April 26&#x02013;May 2), with the highest incidence recorded in Namur. A larger wave followed between weeks 41 (October 11&#x02013;17) and 51 (December 20&#x02013;26), peaking in West Flanders. An exception was seen in Brussels, where a modest increase was noted from week 25 (June 21&#x02013;27), eventually developing into a more substantial wave by week 41.</p><p>During these periods, similar waves could be observed in hospitalizations (<xref rid="pone.0322017.g002" ref-type="fig">Fig 2B</xref>). Between weeks 9 and 17, a considerable increase in hospitalizations was noted in Brussels, Hainaut, and Namur. In Brussels, new hospitalizations increased again from week 25 until West Flanders reached higher incidence rates, particularly peaking around week 47 (November 22&#x02013;28).</p><p>As shown in <xref rid="pone.0322017.g002" ref-type="fig">Fig 2C</xref>, the population percentage that received full primary vaccination increased considerably starting from week 17 (April 26&#x02013;May 2). Every province reached 60% or higher by the end of week 33 (August 16&#x02013;22), except for Brussels. By the end of 2021, West Flanders had the highest coverage of full primary vaccination (77.16%).</p><p>We observed a notable increase in the rate of incoming international travelers across all provinces from week 21 (May 24&#x02013;30) onwards as illustrated in <xref rid="pone.0322017.g002" ref-type="fig">Fig 2D</xref>. However, there was a marked difference in Brussels where it maintained a consistently higher incoming travel rate throughout the year compared to other provinces.</p><p>The COVID-19 test positivity rate among travelers displayed variability over the year, with a general trend that appeared largely similar across the 11 provinces (<xref rid="pone.0322017.g002" ref-type="fig">Fig 2E</xref>). An exception could be observed in week 13 (March 29&#x02013;April 4) when a pronounced peak in positivity rates among travelers who visited Namur was recorded.</p><p>The early months of 2021 were characterized by more stringent measures in Belgium, particularly between week 13 (March 29&#x02013;April 4) and 15 (April 12&#x02013;18, median stringency index = 75.93), as indicated in <xref rid="pone.0322017.g002" ref-type="fig">Fig 2F</xref>. When conditions improved into the summer months, some of these restrictions were relaxed, allowing for greater mobility and fewer constraints on travel. The median stringency index reached its lowest levels between week 41 (October 11&#x02013;17) and 45 (November 8&#x02013;14, median stringeency index = 43.98).</p></sec><sec id="sec008"><title>Fitted linear mixed models</title><sec id="sec009"><title>COVID-19 confirmed cases.</title><p>The model selection process is outlined in <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, sheet S1 Table. Among the 2,900 candidate models evaluated for estimating <inline-formula id="pone.0322017.e016"><alternatives><graphic xlink:href="pone.0322017.e016.jpg" id="pone.0322017.e016g" position="anchor"/><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, one model achieved the lowest AIC value of 965.658, which is given by:</p><disp-formula id="pone.0322017.e017"><alternatives><graphic xlink:href="pone.0322017.e017.jpg" id="pone.0322017.e017g" position="anchor"/><mml:math id="M17" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>14</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>31</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>41</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"/><mml:mtd columnalign="left"/><mml:mtd columnalign="left"><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>51</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>14</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>61</mml:mn></mml:mrow></mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(2)</label></disp-formula><p>with <inline-formula id="pone.0322017.e018"><alternatives><graphic xlink:href="pone.0322017.e018.jpg" id="pone.0322017.e018g" position="anchor"/><mml:math id="M18" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e019"><alternatives><graphic xlink:href="pone.0322017.e019.jpg" id="pone.0322017.e019g" position="anchor"/><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e020"><alternatives><graphic xlink:href="pone.0322017.e020.jpg" id="pone.0322017.e020g" position="anchor"/><mml:math id="M20" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">j</italic>1</sub> mutually independent. This model highlights the important effect of lagged vaccination coverage (<italic toggle="yes">l</italic>&#x02009;=&#x02009;14), incoming travel rates, positivity rates, and the stringency index on the incidence of confirmed cases. Furthermore, significant two-way interactions were identified between lagged vaccination coverage and the stringency index, as well as between travel rates and positivity rates.</p><p>The complete parameter estimates of this model are shown in <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, sheet S2 Table. Using these estimates, we compared the observed incidence of confirmed cases with the 95% prediction intervals, as illustrated in <xref rid="pone.0322017.g003" ref-type="fig">Fig 3</xref>. The observed values consistently fall within the 95% prediction intervals, indicating a good overall fit of the model to the data. Notably, the width of the 95% prediction intervals increases starting from week 41 (October 11&#x02013;17) in all provinces, suggesting greater uncertainty in the model&#x02019;s estimations during this period.</p><fig position="float" id="pone.0322017.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0322017.g003</object-id><label>Fig 3</label><caption><title>Fitted values of the weekly incidence of confirmed cases based on <xref rid="pone.0322017.e017" ref-type="disp-formula">Eq 2</xref>. Observed values are depicted by points around the prediction line.</title></caption><graphic xlink:href="pone.0322017.g003" position="float"/></fig></sec><sec id="sec010"><title>COVID-19 hospitalizations.</title><p>Similar to the confirmed cases, a model with two interaction terms achieved the lowest AIC value of 1061.516 among the 2,900 candidate models. This model is denoted as:</p><disp-formula id="pone.0322017.e021"><alternatives><graphic xlink:href="pone.0322017.e021.jpg" id="pone.0322017.e021g" position="anchor"/><mml:math id="M21" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>02</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>15</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>32</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"/><mml:mtd columnalign="left"/><mml:mtd columnalign="left"><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>52</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>15</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>62</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(3)</label></disp-formula><p>with <inline-formula id="pone.0322017.e022"><alternatives><graphic xlink:href="pone.0322017.e022.jpg" id="pone.0322017.e022g" position="anchor"/><mml:math id="M22" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e023"><alternatives><graphic xlink:href="pone.0322017.e023.jpg" id="pone.0322017.e023g" position="anchor"/><mml:math id="M23" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e024"><alternatives><graphic xlink:href="pone.0322017.e024.jpg" id="pone.0322017.e024g" position="anchor"/><mml:math id="M24" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">j</italic>2</sub> mutually independent. This model highlights again the important effect of lagged vaccination coverage (<italic toggle="yes">l</italic>&#x02009;=&#x02009;15), incoming travel rates, positivity rates, and the stringency index on the incidence of hospitalizations. Significant two-way interactions were found between lagged vaccination coverage and the stringency index, as well as between travel rates and the stringency index.</p><p>All parameter estimates of this model are shown in <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, sheet S3 Table. As shown in <xref rid="pone.0322017.g004" ref-type="fig">Fig 4</xref>, the observed values consistently fall within the 95% prediction intervals. However, we observed a widening of the intervals during two distinct periods: prior to week 17 (April 26&#x02013;-May 2) and after week 41 (October 11&#x02013;-17), across all provinces.</p><fig position="float" id="pone.0322017.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0322017.g004</object-id><label>Fig 4</label><caption><title>Fitted values of the weekly incidence of confirmed cases based on <xref rid="pone.0322017.e021" ref-type="disp-formula">Eq 3</xref>. Observed values are depicted by points around the prediction line.</title></caption><graphic xlink:href="pone.0322017.g004" position="float"/></fig><p>Incorporating the incidence of confirmed cases <inline-formula id="pone.0322017.e025"><alternatives><graphic xlink:href="pone.0322017.e025.jpg" id="pone.0322017.e025g" position="anchor"/><mml:math id="M25" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> as an explanatory variable led to a considerable increase in the number of candidate models, with a total of 50,700 fitted models evaluated. Among these, the model achieving the lowest AIC value (432.708) is given by:</p><disp-formula id="pone.0322017.e026"><alternatives><graphic xlink:href="pone.0322017.e026.jpg" id="pone.0322017.e026g" position="anchor"/><mml:math id="M26" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mo>=</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>02</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>32</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"/><mml:mtd columnalign="left"/><mml:mtd columnalign="left"><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>52</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>62</mml:mn></mml:mrow></mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>72</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"/><mml:mtd columnalign="left"/><mml:mtd columnalign="left"><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></alternatives>
<label>(4)</label></disp-formula><p>with <inline-formula id="pone.0322017.e027"><alternatives><graphic xlink:href="pone.0322017.e027.jpg" id="pone.0322017.e027g" position="anchor"/><mml:math id="M27" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e028"><alternatives><graphic xlink:href="pone.0322017.e028.jpg" id="pone.0322017.e028g" position="anchor"/><mml:math id="M28" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e029"><alternatives><graphic xlink:href="pone.0322017.e029.jpg" id="pone.0322017.e029g" position="anchor"/><mml:math id="M29" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">j</italic>2</sub> mutually independent. A detailed summary of the parameter estimates for this model is provided in <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, sheet S4 Table. This model demonstrated a substantial improvement over the previously reported model in <xref rid="pone.0322017.e021" ref-type="disp-formula">Eq 3</xref>, as evidenced by its notably lower AIC value. The better performance was also reflected in the predictive accuracy, with predictions aligning more closely with observed data, as illustrated in <xref rid="pone.0322017.g005" ref-type="fig">Fig 5</xref>.</p><fig position="float" id="pone.0322017.g005"><object-id pub-id-type="doi">10.1371/journal.pone.0322017.g005</object-id><label>Fig 5</label><caption><title>Fitted values of the weekly incidence of confirmed cases based on <xref rid="pone.0322017.e026" ref-type="disp-formula">Eq 4</xref>. Observed values are depicted by points around the prediction line.</title></caption><graphic xlink:href="pone.0322017.g005" position="float"/></fig></sec><sec id="sec011"><title>Sensitivity analysis.</title><p>The model selection process using data from week 20 is summarized in <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, sheet S5 Table. Consistent with the results obtained from the full dataset, models incorporating <inline-formula id="pone.0322017.e030"><alternatives><graphic xlink:href="pone.0322017.e030.jpg" id="pone.0322017.e030g" position="anchor"/><mml:math id="M30" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> as a predictor led to a substantially lower minimum AIC value compared to those including <inline-formula id="pone.0322017.e031"><alternatives><graphic xlink:href="pone.0322017.e031.jpg" id="pone.0322017.e031g" position="anchor"/><mml:math id="M31" display="inline" overflow="scroll"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula>, indicating a better model fit. An exception was observed, however, in the alternative model for hospitalizations that included <inline-formula id="pone.0322017.e032"><alternatives><graphic xlink:href="pone.0322017.e032.jpg" id="pone.0322017.e032g" position="anchor"/><mml:math id="M32" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> as a predictor. In this case, the model using <inline-formula id="pone.0322017.e033"><alternatives><graphic xlink:href="pone.0322017.e033.jpg" id="pone.0322017.e033g" position="anchor"/><mml:math id="M33" display="inline" overflow="scroll"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></inline-formula> yielded the lowest AIC value, suggesting that the inverse transformation of vaccination coverage better captured the underlying dynamics of the COVID-19 hospitalizations for this shorter period. The formulations of the best-performing models are provided in <xref rid="pone.0322017.t001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="pone.0322017.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0322017.t001</object-id><label>Table 1</label><caption><title>Optimal models to estimate the incidence of confirmed cases and hospitalizations using data from week 20.</title></caption><alternatives><graphic xlink:href="pone.0322017.t001" id="pone.0322017.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Model notation</th><th align="left" rowspan="1" colspan="1">AIC</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0322017.e034">
<alternatives><graphic xlink:href="pone.0322017.e034" id="pone.0322017.e034g" position="anchor"/><mml:math id="M34" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>01</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>15</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>31</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>41</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="2" colspan="1">621.231</td></tr><tr><td align="left" rowspan="1" colspan="1">with <inline-formula id="pone.0322017.e035"><alternatives><graphic xlink:href="pone.0322017.e035" id="pone.0322017.e035g" position="anchor"/><mml:math id="M35" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e036"><alternatives><graphic xlink:href="pone.0322017.e036" id="pone.0322017.e036g" position="anchor"/><mml:math id="M36" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e037"><alternatives><graphic xlink:href="pone.0322017.e037" id="pone.0322017.e037g" position="anchor"/><mml:math id="M37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">j</italic>1</sub> mutually independent.</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0322017.e038">
<alternatives><graphic xlink:href="pone.0322017.e038" id="pone.0322017.e038g" position="anchor"/><mml:math id="M38" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>02</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>23</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>32</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>52</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>23</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>62</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="2" colspan="1">652.114</td></tr><tr><td align="left" rowspan="1" colspan="1">with <inline-formula id="pone.0322017.e039"><alternatives><graphic xlink:href="pone.0322017.e039" id="pone.0322017.e039g" position="anchor"/><mml:math id="M39" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e040"><alternatives><graphic xlink:href="pone.0322017.e040" id="pone.0322017.e040g" position="anchor"/><mml:math id="M40" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e041"><alternatives><graphic xlink:href="pone.0322017.e041" id="pone.0322017.e041g" position="anchor"/><mml:math id="M41" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">j</italic>2</sub> mutually independent.</td></tr><tr><td align="left" rowspan="1" colspan="1">
<inline-formula id="pone.0322017.e042">
<alternatives><graphic xlink:href="pone.0322017.e042" id="pone.0322017.e042g" position="anchor"/><mml:math id="M42" display="inline" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>02</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>32</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>42</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>SI</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>52</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>62</mml:mn></mml:mrow></mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>72</mml:mn></mml:mrow></mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>travel</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b2;</mml:mi><mml:mrow><mml:mn>82</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>vfull</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>&#x000d7;</mml:mi><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>pos</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives>
</inline-formula>
</td><td align="left" rowspan="2" colspan="1">312.963</td></tr><tr><td align="left" rowspan="1" colspan="1">with <inline-formula id="pone.0322017.e043"><alternatives><graphic xlink:href="pone.0322017.e043" id="pone.0322017.e043g" position="anchor"/><mml:math id="M43" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, <inline-formula id="pone.0322017.e044"><alternatives><graphic xlink:href="pone.0322017.e044" id="pone.0322017.e044g" position="anchor"/><mml:math id="M44" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>&#x0223c;</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>&#x003c3;</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></inline-formula>, and <inline-formula id="pone.0322017.e045"><alternatives><graphic xlink:href="pone.0322017.e045" id="pone.0322017.e045g" position="anchor"/><mml:math id="M45" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>&#x003b5;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>, <italic toggle="yes">b</italic><sub>0<italic toggle="yes">j</italic>2</sub> mutually independent.</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="tb1fn01"><p>AIC = Akaike information criterion.</p></fn></table-wrap-foot></table-wrap><p>The parameter estimates of these models are given in <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, sheet S6 Table. The predicted values and their corresponding intervals are presented in <xref rid="pone.0322017.s003" ref-type="supplementary-material">S1 Figure</xref> until <xref rid="pone.0322017.s005" ref-type="supplementary-material">S3 Figure</xref>.</p></sec></sec></sec><sec sec-type="conclusions" id="sec012"><title>Discussion</title><p>In this study, we identified important effects of lagged vaccination coverage, the rate of incoming international travel, the positivity rate among travelers, and the stringency index on the dynamics of COVID-19 confirmed cases and hospitalizations. Furthermore, our results emphasize the potential interactions among these variables, suggesting that their combined impact may be different than merely the sum of their individual contributions.</p><p>Vaccination played a crucial role in reducing the incidence of COVID-19 cases and hospitalizations across various populations and geographic regions [<xref rid="pone.0322017.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0322017.ref033" ref-type="bibr">33</xref>]. Consistent with these findings, our study demonstrates a significant association between vaccination coverage and COVID-19 incidences, as indicated by the negative coefficient of lagged vaccination coverage and/or its interaction term (<xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, S2&#x02013;S4 Tables). For most optimal models, we identified a similar lag <italic toggle="yes">l</italic> of approximately 14-15 weeks. The importance of considering lagged effects when evaluating the impact of vaccination on COVID-19 dynamics has been highlighted in previous research. For instance, Li et al. reported that the lag time for the protective effects of vaccination was approximately 40 days after the administration of the first dose of primary vaccination, with the potential for a rebound in epidemic intensity thereafter [<xref rid="pone.0322017.ref027" ref-type="bibr">27</xref>]. In contrast, Lokonon et al. observed a shorter lag of 15&#x02013;20 days among hospitalized patients and those in intensive care units in Germany [<xref rid="pone.0322017.ref034" ref-type="bibr">34</xref>]. These discrepancies highlight the variability in lag times across different populations and study contexts. Notably, the shorter lag times reported by these studies compared to our findings may stem from differences in methodological approaches, particularly their use of daily data, which allows for finer temporal resolution and capturing more immediate effects.</p><p>While vaccination has been instrumental in providing individual immunity against COVID-19, it does not entirely eliminate the risk of infection [<xref rid="pone.0322017.ref035" ref-type="bibr">35</xref>]. Increased human mobility within a specific timeframe, particularly during periods of high SARS-CoV-2 circulation, elevates the likelihood of contact with an infected individual, thereby amplifying transmission risks. As shown in <xref rid="pone.0322017.g002" ref-type="fig">Fig 2</xref>, we observed a consistent trend starting from week 25 (June 21&#x02013;27) where increases in incoming travel rates and positivity rates among travelers were accompanied by increases in COVID-19 confirmed cases and hospitalizations. This pattern reinforces findings from a previous study in Belgium, which demonstrated that international travel exacerbates COVID-19 incidence and suggested that restricting such travel could significantly mitigate epidemic growth [<xref rid="pone.0322017.ref020" ref-type="bibr">20</xref>]. Similarly, research from Ukraine reported a surge in COVID-19 cases during the summer of 2021, attributed to increased travel and tourism in the absence of travel restrictions [<xref rid="pone.0322017.ref036" ref-type="bibr">36</xref>]. In southern Taiwan, an outbreak in the summer of 2021 was linked to returning travelers from abroad, further underscoring the role of imported cases in local outbreaks [<xref rid="pone.0322017.ref037" ref-type="bibr">37</xref>].</p><p>The evidence collectively suggests that travel volume, particularly during peak periods like summer months, serves as a critical driver of COVID-19 transmission, especially when travelers originate from regions with high incidence rates [<xref rid="pone.0322017.ref038" ref-type="bibr">38</xref>]. However, such risks can be mitigated through targeted interventions, such as frequent testing of travelers and commuters. This approach not only helps identify and isolate potential cases but also reduces the likelihood of widespread transmission, even in contexts where contact reduction policies are less stringent [<xref rid="pone.0322017.ref039" ref-type="bibr">39</xref>]. These findings underscore the importance of integrating mobility management strategies with public health measures to curtail the spread of COVID-19 while balancing the socio-economic demands of the population.</p><p>In addition to vaccination and international travel, several other factors evolved during the investigation period. At the beginning of 2021, the stringency index remained relatively high in response to the resurgence of infections during the fall of 2020 [<xref rid="pone.0322017.ref040" ref-type="bibr">40</xref>]. The restrictions were progressively eased starting from mid-April 2021 as part of a phased relaxation strategy (<xref rid="pone.0322017.g002" ref-type="fig">Fig 2F</xref>) following the nationwide vaccination roll out. The observed decline in stringency measures aligns with broader trends reported in European countries, where increased vaccination coverage facilitated policy shifts towards more lenient restrictions [<xref rid="pone.0322017.ref041" ref-type="bibr">41</xref>]. The strong association between vaccination coverage and the stringency index was further supported by our modeling results, which identified a significant interaction between these two variables (<xref rid="pone.0322017.e017" ref-type="disp-formula">Eq 2</xref> and <xref rid="pone.0322017.e021" ref-type="disp-formula">3</xref>, see also <xref rid="pone.0322017.s002" ref-type="supplementary-material">S2 File</xref>, S2 and S3 Tables). However, we also observed a widening of the 95% prediction intervals in the final weeks of 2021 as presented in <xref rid="pone.0322017.g003" ref-type="fig">Figs 3</xref>&#x02013;<xref rid="pone.0322017.g005" ref-type="fig">5</xref>. This increased variability likely reflects the growing complexity of factors affecting COVID-19 incidences, including changes in dominant SARS-CoV-2 variants. In Belgium, the Alpha variant was predominant during the first half of 2021. However, the Delta variant began its ascent in May 2021, becoming dominant by July 1, 2021, and accounting for nearly 100% of cases by August 1, 2021. Subsequently, the Omicron variant emerged and began circulating in December 2021. These shifts in variants are critical, as each variant exhibits unique transmissibility and immune evasion characteristics [<xref rid="pone.0322017.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0322017.ref043" ref-type="bibr">43</xref>], which introduced additional complexity to the epidemiological landscape, influencing transmission dynamics and the effectiveness of NPIs.</p><p>We found a substantial improvement in model performance when incorporating COVID-19 confirmed cases as a covariate to estimate COVID-19 hospitalizations as indicated by the AIC value (1,061.516 for model in <xref rid="pone.0322017.e021" ref-type="disp-formula">Eq 3</xref> and 432.708 for model in <xref rid="pone.0322017.e026" ref-type="disp-formula">Eq 4</xref>). This result highlights the critical role of confirmed cases in explaining hospitalization trends, as they represent a proximal indicator of disease burden within the population. Including this covariate not only enhanced the predictive accuracy of the model but also enabled a more comprehensive representation of interactions with other variables, such as vaccination coverage and non-pharmaceutical interventions. These interactions are crucial for capturing the multifaceted dynamics influencing hospitalization trends.</p><p>Our sensitivity analysis further revealed that using inverse lagged vaccination coverage as a predictor has a potential to improve model&#x02019;s ability to evaluate COVID-19 hospitalizations. This transformation likely reflects the delayed and non-linear relationship between vaccination efforts and their protective effects at the population level. Specifically, it accounts for diminishing returns in protection as vaccination coverage approaches saturation, variations in immunity due to waning effectiveness, and temporal lags in immunity development post-vaccination. While non-linear mathematical modeling frameworks have frequently addressed such effects [<xref rid="pone.0322017.ref044" ref-type="bibr">44</xref>&#x02013;<xref rid="pone.0322017.ref046" ref-type="bibr">46</xref>], incorporating these transformations into linear models, which are often used in epidemiological research and public health decision-making, remains a valuable approach to bridge the gap between simplicity and the nuanced nature of epidemiological dynamics.</p><p>Some limitations in our analyses should be mentioned. The models employed are statistical and descriptive in nature, designed primarily for interpolation rather than extrapolation. Their application to predictions beyond the observed data ranges of the predictor variables should be approached with caution. When the emphasis is on mobility patterns across different areas such as regions or provinces, a meta-population approach might be of relevance [<xref rid="pone.0322017.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0322017.ref047" ref-type="bibr">47</xref>].</p><p>On top of this, hospitalization data from smaller provinces over certain time periods exhibited significant variability, introducing additional noise into the models. Regional and provincial differences in socio-economic factors, cultural norms, and contact patterns can further complicate the analysis [<xref rid="pone.0322017.ref048" ref-type="bibr">48</xref>,<xref rid="pone.0322017.ref049" ref-type="bibr">49</xref>]. Evidently, this is captured to some extent in the various travel rates. Nevertheless, variations in contact behaviors&#x02013;both domestically and at travel destinations&#x02013;are likely contributors to the observed heterogeneity but remain unaccounted for in this study.</p><p>Further, it should be noted that the stringency index data are only available at the country level, therefore, they do not capture variations in policy stringency at lower administrative levels. The lack of localized data on stringency measures and SARS-CoV-2 variants limited our ability to comprehensively evaluate the impact of non-pharmaceutical interventions (NPIs) and variant-specific dynamics at the provincial level. Additionally, we assume a similar evolution of SARS-CoV-2 variants for the whole country, which may not hold true when considering finer spatial or temporal resolutions. Future studies incorporating more granular data are essential to better disentangle these effects and refine our understanding of the interplay between these variables.</p></sec><sec sec-type="conclusions" id="sec013"><title>Conclusion</title><p>Our findings highlight the complex interplay between public health interventions, population immunity, and mobility patterns in shaping the COVID-19 pandemic. We identified different interaction patterns among the covariates that influence the incidence of COVID-19 confirmed cases and hospitalizations. The best-fitting model for estimating confirmed cases (AIC = 965.658) revealed significant interactions between lagged vaccination coverage and the stringency index, as well as between incoming travel rates and positivity rates. When modeling COVID-19 hospitalizations, a significant interaction was observed between the incoming travel rate and the stringency index. Model performance improved substantially upon incorporating the incidence of confirmed cases as a covariate (AIC = 1,061.516 vs. AIC = 432.708), while highlighting key interactions between confirmed cases and traveler positivity rates, as well as between lagged vaccination coverage and incoming travel rates. For most optimal models, we identified a similar lag <italic toggle="yes">l</italic> of approximately 14-15 weeks. However, this lag duration should be interpreted with caution, as each model includes a different set of interaction terms. These insights contribute to a deeper understanding of the factors driving COVID-19 transmission and healthcare burden, offering valuable guidance for optimizing policy responses in future epidemic scenarios.</p></sec><sec id="sec014" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0322017.s001" position="float" content-type="local-data"><label>S1 File</label><caption><title>Full dataset for fitting the linear mixed models.</title><p>(CSV)</p></caption><media xlink:href="pone.0322017.s001.csv"/></supplementary-material><supplementary-material id="pone.0322017.s002" position="float" content-type="local-data"><label>S2 File</label><caption><title>Model selection process and parameter estimates of the final models (S1&#x02013;S6 Tables).</title><p>(XLSX)</p></caption><media xlink:href="pone.0322017.s002.xlsx"/></supplementary-material><supplementary-material id="pone.0322017.s003" position="float" content-type="local-data"><label>S1 Figure</label><caption><title>Fitted values of the weekly incidence of confirmed cases using data from week 20. Observed values are depicted by points around the prediction line.</title><p>(TIF)</p></caption><media xlink:href="pone.0322017.s003.tif"/></supplementary-material><supplementary-material id="pone.0322017.s004" position="float" content-type="local-data"><label>S2 Figure</label><caption><title>Fitted values of the weekly incidence of hospitalizations (without <inline-formula id="pone.0322017.e046"><alternatives><graphic xlink:href="pone.0322017.e046.jpg" id="pone.0322017.e046g" position="anchor"/><mml:math id="M46" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) using data from week 20. Observed values are depicted by points around the prediction line.</title><p>(TIF)</p></caption><media xlink:href="pone.0322017.s004.tif"/></supplementary-material><supplementary-material id="pone.0322017.s005" position="float" content-type="local-data"><label>S3 Figure</label><caption><title>Fitted values of the weekly incidence of hospitalizations (with <inline-formula id="pone.0322017.e047"><alternatives><graphic xlink:href="pone.0322017.e047.jpg" id="pone.0322017.e047g" position="anchor"/><mml:math id="M47" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mtext>log(IC7)</mml:mtext></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) using data from week 20. Observed values are depicted by points around the prediction line.</title><p>(TIF)</p></caption><media xlink:href="pone.0322017.s005.tif"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0322017.ref001"><label>1</label><mixed-citation publication-type="other">World Health Organization. Coronavirus disease (COVID-19) pandemic. 2024 [Cited October 23, 2024]. Available from: <ext-link xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019" ext-link-type="uri">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link></mixed-citation></ref><ref id="pone.0322017.ref002"><label>2</label><mixed-citation publication-type="other">World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. May 5, 2023 [cited October 23, 2024]. Available from: <ext-link xlink:href="https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?adgroupsurvey=%7Badgroupsurvey%7D%26gclid=EAIaIQobChMI4Ojtsdbe_gIVjQRyCh07igt4EAAYASACEgJ9pfD_BwE%26fbclid=IwAR2M8EAyiSrAodhK9p-X582nHkP2AigpSX8pYIsLsPwqYh4SG26RGokGe7E" ext-link-type="uri">https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?adgroupsurvey=%7Badgroupsurvey%7D%26gclid=EAIaIQobChMI4Ojtsdbe_gIVjQRyCh07igt4EAAYASACEgJ9pfD_BwE%26fbclid=IwAR2M8EAyiSrAodhK9p-X582nHkP2AigpSX8pYIsLsPwqYh4SG26RGokGe7E</ext-link></mixed-citation></ref><ref id="pone.0322017.ref003"><label>3</label><mixed-citation publication-type="other">World Health Organization. WHO coronavirus (COVID-19) dashboard. 2024 [cited October 23, 2024]. Available from: <ext-link xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link></mixed-citation></ref><ref id="pone.0322017.ref004"><label>4</label><mixed-citation publication-type="other">British Broadcasting Corporation. Coronavirus: the world in lockdown in maps and charts. April 7, 2020 [cited February 15, 2022]. Available from: <ext-link xlink:href="https://www.bbc.com/news/world-52103747" ext-link-type="uri">https://www.bbc.com/news/world-52103747</ext-link></mixed-citation></ref><ref id="pone.0322017.ref005"><label>5</label><mixed-citation publication-type="other">European Commission. Council Recommendation (EU) 2020/1475 of 13 October 2020 on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic (Text with EEA relevance). 2020 October 13 [cited October 23, 2024]. Available from: <ext-link xlink:href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32020H1475" ext-link-type="uri">https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32020H1475</ext-link></mixed-citation></ref><ref id="pone.0322017.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Bisanzio</surname><given-names>D</given-names></name>, <name><surname>Reithinger</surname><given-names>R</given-names></name>, <name><surname>Alqunaibet</surname><given-names>A</given-names></name>, <name><surname>Almudarra</surname><given-names>S</given-names></name>, <name><surname>Alsukait</surname><given-names>RF</given-names></name>, <name><surname>Dong</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Estimating the effect of non-pharmaceutical interventions to mitigate COVID-19 spread in Saudi Arabia</article-title>. <source>BMC Med</source>. <year>2022</year>;<volume>20</volume>(<issue>1</issue>):<fpage>51</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12916-022-02232-4</pub-id><pub-id pub-id-type="pmid">35125108</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Fu</surname><given-names>F</given-names></name>. <article-title>Highly coordinated nationwide massive travel restrictions are central to effective mitigation and control of COVID-19 outbreaks in China</article-title>. <source>Proc Math Phys Eng Sci</source>. <year>2022</year>;<volume>478</volume>(<issue>2260</issue>):<fpage>20220040</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rspa.2022.0040</pub-id><pub-id pub-id-type="pmid">35450022</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Kwok</surname><given-names>WC</given-names></name>, <name><surname>Wong</surname><given-names>CK</given-names></name>, <name><surname>Ma</surname><given-names>TF</given-names></name>, <name><surname>Ho</surname><given-names>KW</given-names></name>, <name><surname>Fan</surname><given-names>LW</given-names></name>, <name><surname>Chan</surname><given-names>KF</given-names></name>, <etal>et&#x000a0;al</etal>. Modelling the impact of travel restrictions on COVID-19 cases in Hong Kong in early 2020. <source>BMC Public Health</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>1878</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-021-11889-0</pub-id><pub-id pub-id-type="pmid">34663279</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref009"><label>9</label><mixed-citation publication-type="other">European Centre for Disease Prevention and Control. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. January 31, 2022 [cited February 15, 2022]. Available from: <ext-link xlink:href="https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans" ext-link-type="uri">https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans</ext-link></mixed-citation></ref><ref id="pone.0322017.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Natalia</surname><given-names>YA</given-names></name>, <name><surname>Verbeeck</surname><given-names>J</given-names></name>, <name><surname>Faes</surname><given-names>C</given-names></name>, <name><surname>Neyens</surname><given-names>T</given-names></name>, <name><surname>Molenberghs</surname><given-names>G</given-names></name>. <article-title>Unraveling the impact of the COVID-19 pandemic on the mortality trends in Belgium between 2020&#x02014;2022</article-title>. <source>BMC Public Health</source>. <year>2024</year>;<volume>24</volume>(<issue>1</issue>):<fpage>2916</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-024-20415-x</pub-id><pub-id pub-id-type="pmid">39434002</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref011"><label>11</label><mixed-citation publication-type="other">Sciensano. Belgium COVID-19 epidemiological situation:Vaccination. 2022 [cited February 28, 2022]. Available from: <ext-link xlink:href="https://datastudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/p_j1f02pfnpc" ext-link-type="uri">https://datastudio.google.com/embed/u/0/reporting/c14a5cfc-cab7-4812-848c-0369173148ab/page/p_j1f02pfnpc</ext-link></mixed-citation></ref><ref id="pone.0322017.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Kraemer</surname><given-names>MUG</given-names></name>, <name><surname>Yang</surname><given-names>CH</given-names></name>, <name><surname>Gutierrez</surname><given-names>B</given-names></name>, <name><surname>Wu</surname><given-names>CH</given-names></name>, <name><surname>Klein</surname><given-names>B</given-names></name>, <name><surname>Pigott</surname><given-names>DM</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>The effect of human mobility and control measures on the COVID-19 epidemic in China</article-title>. <source>Science (New York, NY)</source>. <year>2020</year>;<volume>368</volume>(<issue>6490</issue>):<fpage>493</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abb4218</pub-id></mixed-citation></ref><ref id="pone.0322017.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Kissler</surname><given-names>SM</given-names></name>, <name><surname>Kishore</surname><given-names>N</given-names></name>, <name><surname>Prabhu</surname><given-names>M</given-names></name>, <name><surname>Goffman</surname><given-names>D</given-names></name>, <name><surname>Beilin</surname><given-names>Y</given-names></name>, <name><surname>Landau</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Reductions in commuting mobility correlate with geographic differences in SARS-CoV-2 prevalence in New York City</article-title>. <source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>4674</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-020-18271-5</pub-id><pub-id pub-id-type="pmid">32938924</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Wells</surname><given-names>CR</given-names></name>, <name><surname>Sah</surname><given-names>P</given-names></name>, <name><surname>Moghadas</surname><given-names>SM</given-names></name>, <name><surname>Pandey</surname><given-names>A</given-names></name>, <name><surname>Shoukat</surname><given-names>A</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>(<issue>13</issue>):<fpage>7504</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2002616117</pub-id><pub-id pub-id-type="pmid">32170017</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Ensoy-Musoro</surname><given-names>C</given-names></name>, <name><surname>Nguyen</surname><given-names>MH</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <name><surname>Molenberghs</surname><given-names>G</given-names></name>, <name><surname>Faes</surname><given-names>C</given-names></name>. <article-title>Spatio-temporal model to investigate COVID-19 spread accounting for the mobility amongst municipalities</article-title>. <source>Spat Spatiotemporal Epidemiol</source>. <year>2023</year>;<volume>45</volume>:<fpage>100568</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.sste.2023.100568</pub-id>
<pub-id pub-id-type="pmid">37301589</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Scobie</surname><given-names>HM</given-names></name>, <name><surname>Johnson</surname><given-names>AG</given-names></name>, <name><surname>Suthar</surname><given-names>AB</given-names></name>, <name><surname>Severson</surname><given-names>R</given-names></name>, <name><surname>Alden</surname><given-names>NB</given-names></name>, <name><surname>Balter</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. jurisdictions, April 4&#x02013;July 17, 2021</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2021</year>;<volume>70</volume>(<issue>37</issue>):<fpage>1284</fpage>&#x02013;<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.15585/mmwr.mm7037e1</pub-id><pub-id pub-id-type="pmid">34529637</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Ronksley</surname><given-names>P</given-names></name>, <name><surname>Scory</surname><given-names>T</given-names></name>, <name><surname>Weaver</surname><given-names>R</given-names></name>, <name><surname>Lunney</surname><given-names>M</given-names></name>, <name><surname>Rodin</surname><given-names>R</given-names></name>, <name><surname>Tonelli</surname><given-names>M</given-names></name>. <article-title>The impact of vaccination status on importation of COVID-19 among international travellers</article-title>. <source>Canada Commun Dis Rep</source>. <year>2021</year>;<volume>47</volume>(<issue>11</issue>):<fpage>473</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.14745/ccdr.v47i11a05</pub-id></mixed-citation></ref><ref id="pone.0322017.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Greene</surname><given-names>SK</given-names></name>, <name><surname>Levin-Rector</surname><given-names>A</given-names></name>, <name><surname>McGibbon</surname><given-names>E</given-names></name>, <name><surname>Baumgartner</surname><given-names>J</given-names></name>, <name><surname>Devinney</surname><given-names>K</given-names></name>, <name><surname>Ternier</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Reduced COVID-19 hospitalizations among New York City residents following age-based SARS-CoV-2 vaccine eligibility: evidence from a regression discontinuity design</article-title>. <source>Vaccine X</source>. <year>2022</year>;<volume>10</volume>:<fpage>100134</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jvacx.2021.100134</pub-id><pub-id pub-id-type="pmid">34961848</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>W</given-names></name>, <name><surname>Lai</surname><given-names>J</given-names></name>, <name><surname>Hou</surname><given-names>J</given-names></name>, <name><surname>Lin</surname><given-names>W</given-names></name>. <article-title>Vaccination and quarantine effect on COVID-19 transmission dynamics incorporating Chinese-spring-festival travel rush: modeling and simulations</article-title>. <source>Bull Math Biol</source>. <year>2022</year>;<volume>84</volume>(<issue>2</issue>):<fpage>30</fpage>&#x02013;<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11538-021-00958-5</pub-id><pub-id pub-id-type="pmid">35006388</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>MH</given-names></name>, <name><surname>Nguyen</surname><given-names>THT</given-names></name>, <name><surname>Molenberghs</surname><given-names>G</given-names></name>, <name><surname>Abrams</surname><given-names>S</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <name><surname>Faes</surname><given-names>C</given-names></name>. <article-title>The impact of national and international travel on spatio-temporal transmission of SARS-CoV-2 in Belgium in 2021</article-title>. <source>BMC Infect Dis</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>428</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12879-023-08368-9</pub-id><pub-id pub-id-type="pmid">37355572</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref021"><label>21</label><mixed-citation publication-type="other">Sciensano. COVID-19 - datasets. 2022 [cited January 17, 2022]. Available from: <ext-link xlink:href="https://epistat.sciensano.be/covid/" ext-link-type="uri">https://epistat.sciensano.be/covid/</ext-link></mixed-citation></ref><ref id="pone.0322017.ref022"><label>22</label><mixed-citation publication-type="other">Federal Public Service - Health, Food Chain Safety, and Environment. Public health passenger locator form. 2022 [cited January 17, 2022]. Available from: <ext-link xlink:href="https://ibz.be/nl/nieuws/public-health-passenger-locator-form" ext-link-type="uri">https://ibz.be/nl/nieuws/public-health-passenger-locator-form</ext-link></mixed-citation></ref><ref id="pone.0322017.ref023"><label>23</label><mixed-citation publication-type="other">Sciensano. COVID-19 - epidemiologische situatie. 2022 [cited April 30, 2022]. Available from: <ext-link xlink:href="https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie" ext-link-type="uri">https://covid-19.sciensano.be/nl/covid-19-epidemiologische-situatie</ext-link></mixed-citation></ref><ref id="pone.0322017.ref024"><label>24</label><mixed-citation publication-type="other">Our World in Data. COVID-19 data explorer. 2022 [cited April 30, 2022]. Available from: <ext-link xlink:href="https://ourworldindata.org/explorers/covid" ext-link-type="uri">https://ourworldindata.org/explorers/covid</ext-link></mixed-citation></ref><ref id="pone.0322017.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Hale</surname><given-names>T</given-names></name>, <name><surname>Angrist</surname><given-names>N</given-names></name>, <name><surname>Goldszmidt</surname><given-names>R</given-names></name>, <name><surname>Kira</surname><given-names>B</given-names></name>, <name><surname>Petherick</surname><given-names>A</given-names></name>, <name><surname>Phillips</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>A global panel database of pandemic policies (Oxford COVID-19 government response tracker)</article-title>. <source>Nat Hum Behav</source>. <year>2021</year>;<volume>5</volume>:<fpage>529</fpage>&#x02013;<lpage>38</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41562-021-01079-8</pub-id><pub-id pub-id-type="pmid">33686204</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref026"><label>26</label><mixed-citation publication-type="other">Statbel. Population by place of residence, nationality, marital status, age, and sex. 2022 [cited February 15, 2022] Available from: <ext-link xlink:href="https://statbel.fgov.be/en/open-data/population-place-residence-nationality-marital-status-age-and-sex-10" ext-link-type="uri">https://statbel.fgov.be/en/open-data/population-place-residence-nationality-marital-status-age-and-sex-10</ext-link></mixed-citation></ref><ref id="pone.0322017.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Lu</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>. <article-title>Effects of vaccination and non-pharmaceutical interventions and their lag times on the COVID-19 pandemic: comparison of eight countries</article-title>. <source>PLoS Neglected Trop Dis</source>. <year>2022</year>;<volume>16</volume>(<issue>1</issue>):e0010101. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pntd.0010101</pub-id></mixed-citation></ref><ref id="pone.0322017.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Bobrovitz</surname><given-names>N</given-names></name>, <name><surname>Ware</surname><given-names>H</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Hosseini</surname><given-names>R</given-names></name>, <name><surname>Cao</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression</article-title>. <source>Lancet Infect Dis</source>. <year>2023</year>;<volume>23</volume>(<issue>5</issue>):<fpage>556</fpage>-<lpage>567</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00801-5</pub-id><pub-id pub-id-type="pmid">36681084</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref029"><label>29</label><mixed-citation publication-type="journal"><collab>COVID-19 Forecasting Team</collab>. <article-title>Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis</article-title>. <source>Lancet</source>. <year>2023</year>;<volume>401</volume>(<issue>10379</issue>):<fpage>833</fpage>-<lpage>842</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0140-6736(22)02465-5</pub-id><pub-id pub-id-type="pmid">36930674</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>F</given-names></name>, <name><surname>Clemens</surname><given-names>JD</given-names></name>, <name><surname>Zhang</surname><given-names>ZF</given-names></name>, <name><surname>Brewer</surname><given-names>TF</given-names></name>. <article-title>Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States</article-title>. <source>PLoS One</source>. <year>2024</year>;<volume>19</volume>(<issue>4</issue>):e0301830. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0301830</pub-id></mixed-citation></ref><ref id="pone.0322017.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Yamana</surname><given-names>TK</given-names></name>, <name><surname>Galanti</surname><given-names>M</given-names></name>, <name><surname>Pei</surname><given-names>S</given-names></name>, <name><surname>Di Fusco</surname><given-names>M</given-names></name>, <name><surname>Agulo</surname><given-names>FJ</given-names></name>, <name><surname>Moran</surname><given-names>MM</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>The impact of COVID-19 vaccination in the US: Averted burden of SARS-COV-2-related cases, hospitalizations and deaths.</article-title>
<source>PLoS One</source>. <year>2023</year>;<volume>18</volume>(<issue>4</issue>):e0275699. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0275699</pub-id></mixed-citation></ref><ref id="pone.0322017.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Huang</surname><given-names>H</given-names></name>, <name><surname>Ju</surname><given-names>J</given-names></name>, <name><surname>Sun</surname><given-names>R</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>. <article-title>Impact of vaccination on the COVID-19 pandemic in U.S. states</article-title>. <source>Sci Rep</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1554</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-022-05498-z</pub-id><pub-id pub-id-type="pmid">35091640</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>El-Shabasy</surname><given-names>RM</given-names></name>, <name><surname>Nayel</surname><given-names>MA</given-names></name>, <name><surname>Mohamed</surname><given-names>M</given-names></name>, <name><surname>Abdelmonem</surname><given-names>R</given-names></name>, <name><surname>Shoueir</surname><given-names>KR</given-names></name>, <name><surname>Kenawy</surname><given-names>ER</given-names></name>. <article-title>Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic</article-title>. <source>Int J Biol Macromol</source>. <year>2022</year>;<volume>204</volume>:<fpage>161</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2022.01.118</pub-id><pub-id pub-id-type="pmid">35074332</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Lokonon</surname><given-names>BE</given-names></name>, <name><surname>Montcho</surname><given-names>Y</given-names></name>, <name><surname>Klingler</surname><given-names>P</given-names></name>, <name><surname>Tovissod&#x000e9;</surname><given-names>CF</given-names></name> , <name><surname>Gl&#x000e8;l&#x000e8; Kaka&#x000ef;</surname><given-names>R</given-names></name>, <name><surname>Wolkewitz</surname><given-names>M</given-names></name>. <article-title>Lag-time effects of vaccination on SARS-CoV-2 dynamics in German hospitals and intensive-care units</article-title>. <source>Front Public Health</source>. <year>2021</year>;<volume>326</volume>(<issue>20</issue>):<fpage>2043</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fpubh.2023.1085991</pub-id></mixed-citation></ref><ref id="pone.0322017.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Tenforde</surname><given-names>MW</given-names></name>, <name><surname>Self</surname><given-names>WH</given-names></name>, <name><surname>Adams</surname><given-names>K</given-names></name>, <name><surname>Gaglani</surname><given-names>M</given-names></name>, <name><surname>Ginde</surname><given-names>AA</given-names></name>, <name><surname>McNeal</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al</etal> . <article-title>Association between mRNA vaccination and COVID-19 hospitalization and disease severity</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>11</volume>:<fpage>1085991</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2021.19499</pub-id></mixed-citation></ref><ref id="pone.0322017.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Yakovleva</surname><given-names>A</given-names></name>, <name><surname>Kovalenko</surname><given-names>G</given-names></name>, <name><surname>Redlinger</surname><given-names>M</given-names></name>, <name><surname>Liulchuk</surname><given-names>MG</given-names></name>, <name><surname>Bortz</surname><given-names>E</given-names></name>, <name><surname>Zadorozhna</surname><given-names>VI</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Tracking SARS-COV-2 variants using Nanopore sequencing in Ukraine in 2021</article-title>. <source>Sci Rep</source>. <year>2022</year>;<volume>12</volume>(<issue>1</issue>):<fpage>15749</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-022-19414-y</pub-id><pub-id pub-id-type="pmid">36131001</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Shy</surname><given-names>CG</given-names></name>, <name><surname>Lu</surname><given-names>JH</given-names></name>, <name><surname>Lin</surname><given-names>HC</given-names></name>, <name><surname>Hung</surname><given-names>MN</given-names></name>, <name><surname>Chang</surname><given-names>HC</given-names></name>, <name><surname>Lu</surname><given-names>ML</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Rapid Control of a SARS-CoV-2 B.1.617.2 (delta) variant COVID-19 community outbreak: the successful experience in Pingtung County of Taiwan</article-title>. <source>Int J Environ Res Public Health</source>. <year>2022</year>;<volume>19</volume>(<issue>3</issue>):<fpage>1421</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijerph19031421</pub-id><pub-id pub-id-type="pmid">35162443</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Reichmuth</surname><given-names>ML</given-names></name>, <name><surname>Hodcroft</surname><given-names>EB</given-names></name>, <name><surname>Riou</surname><given-names>J</given-names></name>, <name><surname>Neher</surname><given-names>RA</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <name><surname>Althaus</surname><given-names>CL</given-names></name>. <article-title>Impact of cross-border-associated cases on the SARS-CoV-2 epidemic in Switzerland during summer 2020 and 2021</article-title>. <source>Epidemics</source>. <year>2022</year>;<volume>41</volume>:<fpage>100654</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.epidem.2022.100654</pub-id><pub-id pub-id-type="pmid">36444785</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>K&#x000fc;hn</surname><given-names>MJ</given-names></name>, <name><surname>Abele</surname><given-names>D</given-names></name>, <name><surname>Binder</surname><given-names>S</given-names></name>, <name><surname>Rack</surname><given-names>K</given-names></name>, <name><surname>Klitz</surname><given-names>M</given-names></name>, <name><surname>Kleinert</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Regional opening strategies with commuter testing and containment of new SARS-CoV-2 variants in Germany</article-title>. <source>BMC Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>333</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12879-022-07302-9</pub-id><pub-id pub-id-type="pmid">35379190</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Natalia</surname><given-names>YA</given-names></name>, <name><surname>Faes</surname><given-names>C</given-names></name>, <name><surname>Neyens</surname><given-names>T</given-names></name>, <name><surname>Molenberghs</surname><given-names>G</given-names></name>. <article-title>The COVID-19 wave in Belgium during the Fall of 2020 and its association with higher education</article-title>. <source>PLoS One</source>. <year>2022</year>;<volume>17</volume>(<issue>2</issue>):e0264516. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0264516</pub-id></mixed-citation></ref><ref id="pone.0322017.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Ge</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>WB</given-names></name>, <name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Ruktanonchai</surname><given-names>CW</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories</article-title>. <source>Nat Commun</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>3106</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-022-30897-1</pub-id><pub-id pub-id-type="pmid">35661759</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref042"><label>42</label><mixed-citation publication-type="other">World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. 2021 December 28 [cited October 23, 2024]. Available from: <ext-link xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/situation-reports-archive" ext-link-type="uri">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/situation-reports-archive</ext-link></mixed-citation></ref><ref id="pone.0322017.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Carabelli</surname><given-names>AM</given-names></name>, <name><surname>Peacock</surname><given-names>TP</given-names></name>, <name><surname>Thorne</surname><given-names>LG</given-names></name>, <name><surname>Harvey</surname><given-names>WT</given-names></name>, <name><surname>Hughes</surname><given-names>J</given-names></name>, <name><surname>Peacock</surname><given-names>SJ</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>SARS-CoV-2 variant biology: immune escape, transmission and fitness</article-title>. <source>Nat Rev Microbiol</source>. <year>2023</year>;<volume>21</volume>(<issue>3</issue>):<fpage>162</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41579-022-00841-7</pub-id><pub-id pub-id-type="pmid">36653446</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>McBryde</surname><given-names>ES</given-names></name>, <name><surname>Meehan</surname><given-names>MT</given-names></name>, <name><surname>Caldwell</surname><given-names>JM</given-names></name>, <name><surname>Adekunle</surname><given-names>AI</given-names></name>, <name><surname>Ogunlade</surname><given-names>ST</given-names></name>, <name><surname>Kuddus</surname><given-names>MA</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 delta variant in Australia</article-title>. <source>Med J Aust</source>. <year>2021</year>;<volume>215</volume>(<issue>9</issue>):<fpage>427</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5694/mja2.51263</pub-id><pub-id pub-id-type="pmid">34477236</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Kambali</surname><given-names>PN</given-names></name>, <name><surname>Abbasi</surname><given-names>A</given-names></name>, <name><surname>Nataraj</surname><given-names>C</given-names></name>. <article-title>Nonlinear dynamic epidemiological analysis of effects of vaccination and dynamic transmission on COVID-19</article-title>. <source>Nonlinear Dyn</source>. <year>2023</year>;<volume>111</volume>(<issue>1</issue>):<fpage>951</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11071-022-08125-8</pub-id><pub-id pub-id-type="pmid">36530597</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Koshimichi</surname><given-names>H</given-names></name>, <name><surname>Hisaka</surname><given-names>A</given-names></name>. <article-title>Analyzing the worldwide progression of COVID-19 cases and deaths using nonlinear mixed-effects model</article-title>. <source>PLoS One</source>. <year>2024</year>;<volume>19</volume>(<issue>8</issue>):e0306891. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0306891</pub-id></mixed-citation></ref><ref id="pone.0322017.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Parino</surname><given-names>F</given-names></name>, <name><surname>Zino</surname><given-names>L</given-names></name>, <name><surname>Porfiri</surname><given-names>M</given-names></name>, <name><surname>Rizzo</surname><given-names>A</given-names></name>. <article-title>Modelling and predicting the effect of social distancing and travel restrictions on COVID-19 spreading</article-title>. <source>J R Soc Interface</source>. <year>2021</year>;<volume>18</volume>(<issue>175</issue>):<fpage>20200875</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rsif.2020.0875</pub-id><pub-id pub-id-type="pmid">33561374</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Coletti</surname><given-names>P</given-names></name>, <name><surname>Wambua</surname><given-names>J</given-names></name>, <name><surname>Gimma</surname><given-names>A</given-names></name>, <name><surname>Willem</surname><given-names>L</given-names></name>, <name><surname>Vercruysse</surname><given-names>S</given-names></name>, <name><surname>Vanhoutte</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>CoMix: comparing mixing patterns in the Belgian population during and after lockdown</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>21885</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-78540-7</pub-id><pub-id pub-id-type="pmid">33318521</pub-id>
</mixed-citation></ref><ref id="pone.0322017.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>KLM</given-names></name>, <name><surname>Gimma</surname><given-names>A</given-names></name>, <name><surname>Coletti</surname><given-names>P</given-names></name>, <name><surname>Faes</surname><given-names>C</given-names></name>, <name><surname>Beutels</surname><given-names>P</given-names></name>, <name><surname>Hens</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al</etal>. <article-title>Social contact patterns during the COVID-19 pandemic in 21 European countries - evidence from a two-year study</article-title>. <source>BMC Infect Dis</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>268</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12879-023-08214-y</pub-id><pub-id pub-id-type="pmid">37101123</pub-id>
</mixed-citation></ref></ref-list></back><sub-article article-type="author-comment" id="pone.0322017.r001" specific-use="rebutted-decision-letter-unavailable"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r001</article-id><title-group><article-title>Author response to Decision Letter 0</article-title></title-group><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">14 Mar 2024</named-content>
</p></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322017.r002" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r002</article-id><title-group><article-title>Decision Letter 0</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zimmerman</surname><given-names>Steve</given-names></name><role>Staff Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Steve Zimmerman</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Steve Zimmerman</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322017" id="rel-obj002" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>0</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">17 Oct 2024</named-content>
</p><p><!--<div>-->PONE-D-24-10186<!--</div>--><!--<div>-->Empirical association between COVID-19 confirmed cases, hospitalization, vaccination, and travel: Comparison among different regions and provinces in Belgium between April-July 2021<!--</div>--><!--<div>-->PLOS ONE</p><p>Dear Dr. Natalia,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>The manuscript has been evaluated by two reviewers, and their comments are available below.<!--</div>--><!--<div>-->&#x000a0;<!--</div>--><!--<div>-->I am grateful to both of the reviewers for their&#x000a0;detailed assessments of your manuscript. Both reviewers&#x000a0;raised a number of major and minor concerns. They feel the manuscript should outline a clearly-defined research question, and they request improvements to the reporting of methodological and statistical aspects of the study. Please see the two attached files for the full reviews.</p><p>Could you please carefully revise the manuscript to address all comments raised?<!--</div>--><!--<div>--></p><p>Please submit your revised manuscript by Dec 01 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!--</div>--></p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Steve Zimmerman, PhD</p><p>Senior Editor, PLOS ONE</p><p>Journal Requirements:</p><p>When submitting your revision, we need you to address these additional requirements.</p><p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p><p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p><p>
<ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
</p><p>2. We note that [Figure 1] in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <ext-link xlink:href="http://journals.plos.org/plosone/s/licenses-and-copyright." ext-link-type="uri">http://journals.plos.org/plosone/s/licenses-and-copyright</ext-link>.</p><p>We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:</p><p>a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.&#x000a0;</p><p>We recommend that you contact the original copyright holder with the Content Permission Form (<ext-link xlink:href="http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf)" ext-link-type="uri">http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf</ext-link>) and the following text:</p><p>&#x0201c;I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/)." ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.&#x0201d;</p><p>Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.</p><p>In the figure caption of the copyrighted figure, please include the following text: &#x0201c;Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].&#x0201d;</p><p>b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder&#x02019;s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.</p><p>The following resources for replacing copyrighted map figures may be helpful:</p><p>USGS National Map Viewer (public domain): <ext-link xlink:href="http://viewer.nationalmap.gov/viewer/" ext-link-type="uri">http://viewer.nationalmap.gov/viewer/</ext-link></p><p>The Gateway to Astronaut Photography of Earth (public domain): <ext-link xlink:href="http://eol.jsc.nasa.gov/sseop/clickmap/" ext-link-type="uri">http://eol.jsc.nasa.gov/sseop/clickmap/</ext-link></p><p>Maps at the CIA (public domain): <ext-link xlink:href="https://www.cia.gov/library/publications/the-world-factbook/index.html" ext-link-type="uri">https://www.cia.gov/library/publications/the-world-factbook/index.html</ext-link> and <ext-link xlink:href="https://www.cia.gov/library/publications/cia-maps-publications/index.html" ext-link-type="uri">https://www.cia.gov/library/publications/cia-maps-publications/index.html</ext-link></p><p>NASA Earth Observatory (public domain): <ext-link xlink:href="http://earthobservatory.nasa.gov/" ext-link-type="uri">http://earthobservatory.nasa.gov/</ext-link></p><p>Landsat: <ext-link xlink:href="http://landsat.visibleearth.nasa.gov/" ext-link-type="uri">http://landsat.visibleearth.nasa.gov/</ext-link></p><p>USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <ext-link xlink:href="http://eros.usgs.gov/#" ext-link-type="uri">http://eros.usgs.gov/#</ext-link></p><p>Natural Earth (public domain): <ext-link xlink:href="http://www.naturalearthdata.com/" ext-link-type="uri">http://www.naturalearthdata.com/</ext-link></p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #1:&#x000a0;Partly</p><p>Reviewer #2:&#x000a0;Partly</p><p>**********</p><p><!--<font color="black">-->2. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #1:&#x000a0;I Don't Know</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #1:&#x000a0;Yes</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->4. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->5. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #1:&#x000a0;see attachment for comments</p><p>Reviewer #2:&#x000a0;The article ``Empirical association between COVID-19 confirmed cases,</p><p>hospitalization, vaccination, and travel [...]'' by Yessika Adelwin Natalia et al. presents a statistical analysis between the mentioned explanatory and to be explained variables. One should maybe add ``international'' or better ``air'' in the title in front of travel, as other travel is not considered.</p><p>Please see attached pdf for detailed review comments.</p><p>**********</p><p><!--<font color="black">-->6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #1:&#x000a0;No</p><p>Reviewer #2:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p></body></sub-article><sub-article article-type="author-comment" id="pone.0322017.r003"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r003</article-id><title-group><article-title>Author response to Decision Letter 1</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322017" id="rel-obj003" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">21 Jan 2025</named-content>
</p><p>We want to thank the editor and reviewers for their critical assessment of our manuscript and their constructive comments. We have addressed all of them and modified the paper accordingly. Please find our detailed response in a separate document.</p><supplementary-material id="pone.0322017.s006" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response to reviewers.pdf</named-content></p></caption><media xlink:href="pone.0322017.s006.pdf"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322017.r004" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r004</article-id><title-group><article-title>Decision Letter 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aouissi</surname><given-names>Hani Amir</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Hani Amir Aouissi</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Hani Amir Aouissi</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322017" id="rel-obj004" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">20 Feb 2025</named-content>
</p><p><!--<div>-->PONE-D-24-10186R1<!--</div>--><!--<div>-->Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021<!--</div>--><!--<div>-->PLOS ONE</p><p>Dear Dr. Natalia,</p><p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#x02019;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p><p>Please submit your revised manuscript by Apr 06 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at&#x000a0;<email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p><p>Please include the following items when submitting your revised manuscript:<!--</div>--></p><p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list>
</p><p><!--<div>-->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p><p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&#x00026;utm_source=authorletters&#x00026;utm_campaign=protocols</ext-link>.</p><p>We look forward to receiving your revised manuscript.</p><p>Kind regards,</p><p>Dr. Hani Amir Aouissi</p><p>Academic Editor</p><p>PLOS ONE</p><p>Journal Requirements:</p><p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article&#x02019;s retracted status in the References list and also include a citation and full reference for the retraction notice.</p><p>[Note: HTML markup is below. Please do not edit.]</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!--</font>--></p><p>Reviewer #2:&#x000a0;All comments have been addressed</p><p>Reviewer #3:&#x000a0;(No Response)</p><p>**********</p><p><!--<font color="black">-->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #2:&#x000a0;Yes</p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #2:&#x000a0;(No Response)</p><p>Reviewer #3:&#x000a0;It was a pleasure for me to read this paper:</p><p>Title : &#x000ab; Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021 &#x000bb;,</p><p>Reference : PONE-D-24-10186R1</p><p>Journal : PLOS ONE.</p><p>After reviewing it, I think the paper is very qualitative. In addition, given the fact that this is a revised version, the authors previously improved the overall level of their manuscript, this is why I will just give some minor comments in order to help to optimize the quality, if you don&#x02019;t mind here are some comments below :</p><p>1. In the abstract section : &#x000ab;&#x02026;The analysis revealed crucial effects of these factors on the dynamics of COVID-19 cases and hospitalizations. Notably, the results suggest potential interactions among these variables, indicating that their combined effects may differ from the sum of their individual contributions&#x02026; &#x000bb;. I think you have to support your statements by adding some results (numbers).</p><p>2. Lines 38-45, I appreciated the justification of your study. Nevertheless, I think you have to finish your abstract by clearly specifying the aim of your study, It may help the readers to better understand what you&#x02019;ve done and why.</p><p>3. Fig 1. Normally the scale should be put in the lower part of the map . In addition, please add the North direction and the source (eg. Authors) if you have drawn it.</p><p>4. I suggest dividing your materials &#x00026; methods section into 3 subsections: 1. Study Area 2. Data 3. Statistical Methods. You can include a revised version of your map and adding some information about Belgium in general.</p><p>5. Isn't there more recent data than 2021? I think we should try to justify this by explaining this in the manuscript ?</p><p>6.Line 171, you mean AIC= 432.708 ? If yes, please specify</p><p>7. I think there is a lack of references in the discussion section, I recommend to discuss the findings of the following papers, or to read them (if not the case) in addition of other manuscripts, here are only examples:</p><p>Doi: 10.1038/s41598-022-05498-z / Doi: 10.1016/j.ijbiomac.2022.01.118 / Doi: 10.3390/vaccines10111781 / Doi: 10.1080/01559982.2022.2045418</p><p>8. Same comment as the abstract section, please consider improving your discussion by emphasizing some quantitative results to support some statements.</p><p>9. Line 258-291, please avoid using first, second,&#x02026;etc while describing your limitations.</p><p>10.Conclusion sections looks a little weak, please try to extend it a bit.</p><p>11. The references are well chosen and the majority are recent, it was a good job. Again, I just suggest to increase their number in order to better support your work.</p><p>**********</p><p><!--<font color="black">-->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #2:&#x000a0;No</p><p>Reviewer #3:&#x000a0;No</p><p>**********</p><p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p><p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,&#x000a0;<ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at&#x000a0;<email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.<!--</div>--></p><supplementary-material id="pone.0322017.s007" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">review_2.pdf</named-content></p></caption><media xlink:href="pone.0322017.s007.pdf"/></supplementary-material></body></sub-article><sub-article article-type="author-comment" id="pone.0322017.r005"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r005</article-id><title-group><article-title>Author response to Decision Letter 2</article-title></title-group><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322017" id="rel-obj005" related-article-type="editor-report"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="author-response-date">6 Mar 2025</named-content>
</p><p>We thank the reviewers for their time and effort in reviewing our revised manuscript and for the nice appraisal of our work. We have addressed all comments in a separate document.</p><supplementary-material id="pone.0322017.s008" position="float" content-type="local-data"><label>Attachment</label><caption><p>Submitted filename: <named-content content-type="submitted-filename">Response_to_reviewers_auresp_2.pdf</named-content></p></caption><media xlink:href="pone.0322017.s008.pdf"/></supplementary-material></body></sub-article><sub-article article-type="aggregated-review-documents" id="pone.0322017.r006" specific-use="decision-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r006</article-id><title-group><article-title>Decision Letter 2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aouissi</surname><given-names>Hani Amir</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Hani Amir Aouissi</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Hani Amir Aouissi</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322017" id="rel-obj006" related-article-type="reviewed-article"/><custom-meta-group><custom-meta><meta-name>Submission Version</meta-name><meta-value>2</meta-value></custom-meta></custom-meta-group></front-stub><body><p>
<named-content content-type="letter-date">16 Mar 2025</named-content>
</p><p>Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021</p><p>PONE-D-24-10186R2</p><p>Dear Dr. Natalia,</p><p>We&#x02019;re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p><p>Within one week, you&#x02019;ll receive an e-mail detailing the required amendments. When these have been addressed, you&#x02019;ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p><p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">Editorial Manager&#x000ae;</ext-link>&#x000a0;and clicking the &#x02018;Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.</p><p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they&#x02019;ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>Kind regards,</p><p>Hani Amir Aouissi</p><p>Academic Editor</p><p>PLOS ONE</p><p>Additional Editor Comments (optional):</p><p>Reviewers' comments:</p><p>Reviewer's Responses to Questions</p><p>
<!--<font color="black">-->
<bold>Comments to the Author</bold>
</p><p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the &#x0201c;Comments to the Author&#x0201d; section, enter your conflict of interest statement in the &#x0201c;Confidential to Editor&#x0201d; section, and submit your "Accept" recommendation.<!--</font>--></p><p>Reviewer #3:&#x000a0;All comments have been addressed</p><p>**********</p><p><!--<font color="black">-->2. Is the manuscript technically sound, and do the data support the conclusions?</p><p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. <!--</font>--></p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->3. Has the statistical analysis been performed appropriately and rigorously? <!--</font>--></p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->4. Have the authors made all data underlying the findings in their manuscript fully available?</p><p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data&#x02014;e.g. participant privacy or use of data from a third party&#x02014;those must be specified.<!--</font>--></p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->5. Is the manuscript presented in an intelligible fashion and written in standard English?</p><p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.<!--</font>--></p><p>Reviewer #3:&#x000a0;Yes</p><p>**********</p><p><!--<font color="black">-->6. Review Comments to the Author</p><p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!--</font>--></p><p>Reviewer #3:&#x000a0;The revised version of the manuscript titled &#x000ab; Empirical analysis of COVID-19 confirmed cases,</p><p>hospitalizations, vaccination, and international travel across Belgian provinces in 2021&#x000a0;&#x000bb;, Ref &#x000ab;&#x000a0;PONE-D-</p><p>24-10186R2&#x000a0;&#x000bb; was well handled.</p><p>The authors responded to almost all my comments and suggesstions and made appropriate qualitative</p><p>revisions in the main text, I think that it was a very good job and that the paper is now suitable for</p><p>publication in my humble opinion.</p><p>Thank you again for the opportunity to read this article.</p><p>**********</p><p><!--<font color="black">-->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p><p>If you choose &#x0201c;no&#x0201d;, your identity will remain anonymous but your review may still be made public.</p><p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!--</font>--></p><p>Reviewer #3:&#x000a0;No</p><p>**********</p></body></sub-article><sub-article article-type="editor-report" id="pone.0322017.r007" specific-use="acceptance-letter"><front-stub><article-id pub-id-type="doi">10.1371/journal.pone.0322017.r007</article-id><title-group><article-title>Acceptance letter</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aouissi</surname><given-names>Hani Amir</given-names></name><role>Academic Editor</role></contrib></contrib-group><permissions><copyright-statement>&#x000a9; 2025 Hani Amir Aouissi</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Hani Amir Aouissi</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0322017" id="rel-obj007" related-article-type="reviewed-article"/></front-stub><body><p>PONE-D-24-10186R2</p><p>PLOS ONE</p><p>Dear Dr. Natalia,</p><p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p><p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p><p>* All references, tables, and figures are properly cited</p><p>* All relevant supporting information is included in the manuscript submission,</p><p>* There are no issues that prevent the paper from being properly typeset</p><p>If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.</p><p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p><p>If we can help with anything else, please email us at customercare@plos.org.</p><p>Thank you for submitting your work to PLOS ONE and supporting open access.</p><p>Kind regards,</p><p>PLOS ONE Editorial Office Staff</p><p>on behalf of</p><p>Dr. Hani Amir Aouissi</p><p>Academic Editor</p><p>PLOS ONE</p></body></sub-article></article>